AIM ImmunoTech Inc.
AIMNYSE
$0.26
↓ -5.9%Jul 17 close · end-of-day
Price
1Y↓ -97.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.1M
Enterprise Value
-$546,677.61
P/E
—
P/S
11.9
P/B
0.5
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$94,000.00
Net Income (TTM)
-$13.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-10926.6%
Net Margin
-14123.4%
ROE
-624.8%
ROIC
-1763.9%
Debt / Equity
2.0
Net Cash
$1.7M
Return 1Y
-97.0%
Company profile
AIM ImmunoTech Inc. focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS) It is also developing Ampligen for the. treatment of renal cell carcinoma, malignant melanoma,. non-small cell lung, ovarian, breast,. breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis
- CEO
- Thomas K. Equels
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- Florida
- Website
- aimimmuno.com
Earnings
AIM Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$22,000.00↑ +37.5%
Diluted EPS-$0.69↑ +1280.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $163,000.00 | $135,000.00 | $141,000.00 | $202,000.00 | $170,000.00 | $88,000.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$15.2M | -$18.8M | -$19.9M | -$31.9M | -$19.8M | -$11.7M |
| Net income | -$14.4M | -$19.1M | -$19.4M | -$29.0M | -$17.3M | -$14.0M |
| Diluted EPS | — | — | -$0.40 | -$0.60 | -$30.92 | -$8.62 |
| Operating cash flow | -$10.4M | -$14.0M | -$16.1M | -$21.3M | -$14.9M | -$11.0M |
| Free cash flow | -$10.4M | -$14.0M | -$16.2M | — | -$14.9M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -9295.7% | -13954.1% | -14129.8% | -15800.0% | -11630.6% | -13254.5% |
| Net margin | -8834.4% | -14168.1% | -13790.8% | -14337.6% | -10188.2% | -15861.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $50,000.00 | $35,000.00 | $45,000.00 | $16,000.00 | $25,000.00 | $26,000.00 | $21,000.00 | $22,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.7M | -$4.5M | -$5.9M | -$3.6M | -$2.6M | -$2.4M | -$3.0M | -$2.2M |
| Net income | -$1.8M | -$3.7M | -$6.0M | -$3.7M | -$2.8M | -$3.3M | -$4.2M | -$3.0M |
| Diluted EPS | -$3.00 | -$6.00 | -$21.80 | -$0.05 | -$3.68 | $1.57 | -$6.46 | -$0.69 |
| Operating cash flow | -$3.0M | -$3.1M | -$4.0M | -$2.4M | -$1.5M | -$5.1M | -$2.0M | -$2.7M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -7388.0% | -12825.7% | -13011.1% | -22618.8% | -10584.0% | -9411.5% | -14057.1% | -10118.2% |
| Net margin | -3672.0% | -10571.4% | -13260.0% | -23156.3% | -11176.0% | -12630.8% | -19881.0% | -13740.9% |
Company news
Jun 22, 2026
Jun 18, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-12 | Equels Thomas K.· CEO & President | C | 25,000 | $0.00 | $0.00 | filing |
| 2026-03-12 | CHEMEROW DAVID I. | C | 25,000 | $0.00 | $0.00 | filing |
| 2026-02-05 | CHEMEROW DAVID I. | Award | 2,800 | $1.23 | $3,444.00 | filing |
Latest 3 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.